Achievement of more stringent disease control is associated with reduced burden on workplace and household productivity: results from long-term certolizumab pegol treatment in patients with psoriatic arthritis

William Tillett; Laura C. Coates; Sandeep Kiri; Vanessa Taieb; Damon Willems; Philip J. Mease

doi:10.1177/1759720X221140846

Achievement of more stringent disease control is associated with reduced burden on workplace and household productivity: results from long-term certolizumab pegol treatment in patients with psoriatic arthritis

William Tillett, Laura C. Coates, Sandeep Kiri, Vanessa Taieb, Damon Willems, Philip J. Mease

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Psoriatic arthritis (PsA) impacts the physical health and functional ability of patients, leading to reduced productivity. High unemployment rates and absence due to sickness have been reported in patients with PsA. Objectives: This post hoc study investigated certolizumab pegol treatment impact on workplace and household productivity in patients with PsA, and assessed whether achievement of more stringent disease control was associated with greater improvements in productivity. Design: RAPID-PsA was a 216-week phase III trial. Methods: This post hoc study used a generalised estimating equations (GEE) model to examine the disease activity association, measured using American College of Rheumatology (ACR) and Disease Activity in PSoriatic Arthritis (DAPSA), and workplace and household productivity, assessed using an arthritis-specific Work Productivity Survey (WPS). The GEE model estimated the mean cumulative number of days patients meeting different disease control criteria were affected by absenteeism or presenteeism in the workplace and household. Results: In all, 273 patients were randomised to certolizumab pegol and 183 (67.0%) completed Week 216. At baseline, 60.8% of patients were employed outside the home. Improved disease control, measured using ACR and DAPSA criteria, was associated with fewer cumulative days affected by workplace absenteeism through Week 216: ACR70: 4.1 days, ACR50 to <70: 7.7, ACR20 to <50: 20.9, <ACR20: 35.7; DAPSA remission (REM): 3.3, low disease activity (LDA): 9.8, moderate disease activity (MoDA): 22.4, high disease activity (HDA): 54.0. Improved disease control was also associated with fewer days affected by workplace presenteeism: ACR70: 5.6, ACR50 to <70: 19.3, ACR20 to <50: 71.2, < ACR20: 141.2; DAPSA REM: 5.7, LDA: 25.8, MoDA: 77.2, HDA: 223.6. Similar associations between greater disease control and improved productivity were observed for household absenteeism and presenteeism. Conclusion: This post hoc study demonstrates the cumulative workplace and household work productivity benefits for patients with PsA when achieving more stringent thresholds of disease control with certolizumab pegol treatment.

Original language	English
Pages (from-to)	1-12
Journal	Therapeutic Advances in Musculoskeletal Disease
Volume	14
Early online date	13 Dec 2022
DOIs	https://doi.org/10.1177/1759720X221140846
Publication status	Published - 31 Dec 2022

Bibliographical note

Funding Information:
The authors thank the patients, the investigators and their teams who took part in this study. The authors acknowledge Tommi Nurminen for contributing to the development of the analyses and David Deering, Domenico Magazzu and Otis Rimmer for contributing to the programming of these analyses. The authors also acknowledge Heather Edens, PhD, UCB Pharma, Smyrna, GA, USA, for publication coordination and editorial assistance and Sona Popat, BA, and Lucy Berry, MBBS, from Costello Medical, UK, for medical writing and editorial assistance based on the authors’ input and direction. This study was funded by UCB Pharma. All costs associated with the development of this manuscript were funded by UCB Pharma. The authors disclosed receipt of the following financial support for the research, authorship and/or publication of this article: This study was sponsored by UCB Pharma. This manuscript was based on the original study RAPID-PsA (NCT01087788) sponsored by UCB Pharma. Support for third-party writing assistance for this article, provided by Sona Popat, BA, and Lucy Berry, MBBS, Costello Medical, UK, was funded by UCB Pharma in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).

Funding Information:
The authors thank the patients, the investigators and their teams who took part in this study. The authors acknowledge Tommi Nurminen for contributing to the development of the analyses and David Deering, Domenico Magazzu and Otis Rimmer for contributing to the programming of these analyses. The authors also acknowledge Heather Edens, PhD, UCB Pharma, Smyrna, GA, USA, for publication coordination and editorial assistance and Sona Popat, BA, and Lucy Berry, MBBS, from Costello Medical, UK, for medical writing and editorial assistance based on the authors’ input and direction. This study was funded by UCB Pharma. All costs associated with the development of this manuscript were funded by UCB Pharma.

Publisher Copyright:
© The Author(s), 2022.

Keywords

certolizumab pegol
disease control
psoriatic arthritis
treatment targets
work productivity

ASJC Scopus subject areas

Rheumatology
Orthopedics and Sports Medicine

Access to Document

10.1177/1759720X221140846Licence: CC BY

Fingerprint

Dive into the research topics of 'Achievement of more stringent disease control is associated with reduced burden on workplace and household productivity: results from long-term certolizumab pegol treatment in patients with psoriatic arthritis'. Together they form a unique fingerprint.

The Impact of Biologic and Targeted Synthetic Disease Modifying Drugs in Psoriatic Arthritis
Tillett, W. (PI)
Project: UK industry

Cite this

Tillett, W., Coates, L. C., Kiri, S., Taieb, V., Willems, D., & Mease, P. J. (2022). Achievement of more stringent disease control is associated with reduced burden on workplace and household productivity: results from long-term certolizumab pegol treatment in patients with psoriatic arthritis. Therapeutic Advances in Musculoskeletal Disease, 14, 1-12. https://doi.org/10.1177/1759720X221140846

Achievement of more stringent disease control is associated with reduced burden on workplace and household productivity: results from long-term certolizumab pegol treatment in patients with psoriatic arthritis. / Tillett, William; Coates, Laura C.; Kiri, Sandeep et al.
In: Therapeutic Advances in Musculoskeletal Disease, Vol. 14, 31.12.2022, p. 1-12.

Research output: Contribution to journal › Article › peer-review

Tillett, W, Coates, LC, Kiri, S, Taieb, V, Willems, D & Mease, PJ 2022, 'Achievement of more stringent disease control is associated with reduced burden on workplace and household productivity: results from long-term certolizumab pegol treatment in patients with psoriatic arthritis', Therapeutic Advances in Musculoskeletal Disease, vol. 14, pp. 1-12. https://doi.org/10.1177/1759720X221140846

Tillett W, Coates LC, Kiri S, Taieb V, Willems D, Mease PJ. Achievement of more stringent disease control is associated with reduced burden on workplace and household productivity: results from long-term certolizumab pegol treatment in patients with psoriatic arthritis. Therapeutic Advances in Musculoskeletal Disease. 2022 Dec 31;14:1-12. Epub 2022 Dec 13. doi: 10.1177/1759720X221140846

@article{287253fad7ed4ffdb564c432082294e5,

title = "Achievement of more stringent disease control is associated with reduced burden on workplace and household productivity: results from long-term certolizumab pegol treatment in patients with psoriatic arthritis",

abstract = "Background: Psoriatic arthritis (PsA) impacts the physical health and functional ability of patients, leading to reduced productivity. High unemployment rates and absence due to sickness have been reported in patients with PsA. Objectives: This post hoc study investigated certolizumab pegol treatment impact on workplace and household productivity in patients with PsA, and assessed whether achievement of more stringent disease control was associated with greater improvements in productivity. Design: RAPID-PsA was a 216-week phase III trial. Methods: This post hoc study used a generalised estimating equations (GEE) model to examine the disease activity association, measured using American College of Rheumatology (ACR) and Disease Activity in PSoriatic Arthritis (DAPSA), and workplace and household productivity, assessed using an arthritis-specific Work Productivity Survey (WPS). The GEE model estimated the mean cumulative number of days patients meeting different disease control criteria were affected by absenteeism or presenteeism in the workplace and household. Results: In all, 273 patients were randomised to certolizumab pegol and 183 (67.0%) completed Week 216. At baseline, 60.8% of patients were employed outside the home. Improved disease control, measured using ACR and DAPSA criteria, was associated with fewer cumulative days affected by workplace absenteeism through Week 216: ACR70: 4.1 days, ACR50 to <70: 7.7, ACR20 to <50: 20.9, ",

keywords = "certolizumab pegol, disease control, psoriatic arthritis, treatment targets, work productivity",

author = "William Tillett and Coates, {Laura C.} and Sandeep Kiri and Vanessa Taieb and Damon Willems and Mease, {Philip J.}",

note = "Funding Information: The authors thank the patients, the investigators and their teams who took part in this study. The authors acknowledge Tommi Nurminen for contributing to the development of the analyses and David Deering, Domenico Magazzu and Otis Rimmer for contributing to the programming of these analyses. The authors also acknowledge Heather Edens, PhD, UCB Pharma, Smyrna, GA, USA, for publication coordination and editorial assistance and Sona Popat, BA, and Lucy Berry, MBBS, from Costello Medical, UK, for medical writing and editorial assistance based on the authors{\textquoteright} input and direction. This study was funded by UCB Pharma. All costs associated with the development of this manuscript were funded by UCB Pharma. The authors disclosed receipt of the following financial support for the research, authorship and/or publication of this article: This study was sponsored by UCB Pharma. This manuscript was based on the original study RAPID-PsA (NCT01087788) sponsored by UCB Pharma. Support for third-party writing assistance for this article, provided by Sona Popat, BA, and Lucy Berry, MBBS, Costello Medical, UK, was funded by UCB Pharma in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3). Funding Information: The authors thank the patients, the investigators and their teams who took part in this study. The authors acknowledge Tommi Nurminen for contributing to the development of the analyses and David Deering, Domenico Magazzu and Otis Rimmer for contributing to the programming of these analyses. The authors also acknowledge Heather Edens, PhD, UCB Pharma, Smyrna, GA, USA, for publication coordination and editorial assistance and Sona Popat, BA, and Lucy Berry, MBBS, from Costello Medical, UK, for medical writing and editorial assistance based on the authors{\textquoteright} input and direction. This study was funded by UCB Pharma. All costs associated with the development of this manuscript were funded by UCB Pharma. Publisher Copyright: {\textcopyright} The Author(s), 2022.",

year = "2022",

month = dec,

day = "31",

doi = "10.1177/1759720X221140846",

language = "English",

volume = "14",

pages = "1--12",

journal = "Therapeutic Advances in Musculoskeletal Disease",

issn = "1759-720X",

publisher = "Sage Publications",

}

TY - JOUR

T1 - Achievement of more stringent disease control is associated with reduced burden on workplace and household productivity

T2 - results from long-term certolizumab pegol treatment in patients with psoriatic arthritis

AU - Tillett, William

AU - Coates, Laura C.

AU - Kiri, Sandeep

AU - Taieb, Vanessa

AU - Willems, Damon

AU - Mease, Philip J.

N1 - Funding Information: The authors thank the patients, the investigators and their teams who took part in this study. The authors acknowledge Tommi Nurminen for contributing to the development of the analyses and David Deering, Domenico Magazzu and Otis Rimmer for contributing to the programming of these analyses. The authors also acknowledge Heather Edens, PhD, UCB Pharma, Smyrna, GA, USA, for publication coordination and editorial assistance and Sona Popat, BA, and Lucy Berry, MBBS, from Costello Medical, UK, for medical writing and editorial assistance based on the authors’ input and direction. This study was funded by UCB Pharma. All costs associated with the development of this manuscript were funded by UCB Pharma. The authors disclosed receipt of the following financial support for the research, authorship and/or publication of this article: This study was sponsored by UCB Pharma. This manuscript was based on the original study RAPID-PsA (NCT01087788) sponsored by UCB Pharma. Support for third-party writing assistance for this article, provided by Sona Popat, BA, and Lucy Berry, MBBS, Costello Medical, UK, was funded by UCB Pharma in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3). Funding Information: The authors thank the patients, the investigators and their teams who took part in this study. The authors acknowledge Tommi Nurminen for contributing to the development of the analyses and David Deering, Domenico Magazzu and Otis Rimmer for contributing to the programming of these analyses. The authors also acknowledge Heather Edens, PhD, UCB Pharma, Smyrna, GA, USA, for publication coordination and editorial assistance and Sona Popat, BA, and Lucy Berry, MBBS, from Costello Medical, UK, for medical writing and editorial assistance based on the authors’ input and direction. This study was funded by UCB Pharma. All costs associated with the development of this manuscript were funded by UCB Pharma. Publisher Copyright: © The Author(s), 2022.

PY - 2022/12/31

Y1 - 2022/12/31

N2 - Background: Psoriatic arthritis (PsA) impacts the physical health and functional ability of patients, leading to reduced productivity. High unemployment rates and absence due to sickness have been reported in patients with PsA. Objectives: This post hoc study investigated certolizumab pegol treatment impact on workplace and household productivity in patients with PsA, and assessed whether achievement of more stringent disease control was associated with greater improvements in productivity. Design: RAPID-PsA was a 216-week phase III trial. Methods: This post hoc study used a generalised estimating equations (GEE) model to examine the disease activity association, measured using American College of Rheumatology (ACR) and Disease Activity in PSoriatic Arthritis (DAPSA), and workplace and household productivity, assessed using an arthritis-specific Work Productivity Survey (WPS). The GEE model estimated the mean cumulative number of days patients meeting different disease control criteria were affected by absenteeism or presenteeism in the workplace and household. Results: In all, 273 patients were randomised to certolizumab pegol and 183 (67.0%) completed Week 216. At baseline, 60.8% of patients were employed outside the home. Improved disease control, measured using ACR and DAPSA criteria, was associated with fewer cumulative days affected by workplace absenteeism through Week 216: ACR70: 4.1 days, ACR50 to <70: 7.7, ACR20 to <50: 20.9,

AB - Background: Psoriatic arthritis (PsA) impacts the physical health and functional ability of patients, leading to reduced productivity. High unemployment rates and absence due to sickness have been reported in patients with PsA. Objectives: This post hoc study investigated certolizumab pegol treatment impact on workplace and household productivity in patients with PsA, and assessed whether achievement of more stringent disease control was associated with greater improvements in productivity. Design: RAPID-PsA was a 216-week phase III trial. Methods: This post hoc study used a generalised estimating equations (GEE) model to examine the disease activity association, measured using American College of Rheumatology (ACR) and Disease Activity in PSoriatic Arthritis (DAPSA), and workplace and household productivity, assessed using an arthritis-specific Work Productivity Survey (WPS). The GEE model estimated the mean cumulative number of days patients meeting different disease control criteria were affected by absenteeism or presenteeism in the workplace and household. Results: In all, 273 patients were randomised to certolizumab pegol and 183 (67.0%) completed Week 216. At baseline, 60.8% of patients were employed outside the home. Improved disease control, measured using ACR and DAPSA criteria, was associated with fewer cumulative days affected by workplace absenteeism through Week 216: ACR70: 4.1 days, ACR50 to <70: 7.7, ACR20 to <50: 20.9,

KW - certolizumab pegol

KW - disease control

KW - psoriatic arthritis

KW - treatment targets

KW - work productivity

UR - http://www.scopus.com/inward/record.url?scp=85144094742&partnerID=8YFLogxK

U2 - 10.1177/1759720X221140846

DO - 10.1177/1759720X221140846

M3 - Article

AN - SCOPUS:85144094742

SN - 1759-720X

VL - 14

SP - 1

EP - 12

JO - Therapeutic Advances in Musculoskeletal Disease

JF - Therapeutic Advances in Musculoskeletal Disease

ER -

Achievement of more stringent disease control is associated with reduced burden on workplace and household productivity: results from long-term certolizumab pegol treatment in patients with psoriatic arthritis

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Projects

The Impact of Biologic and Targeted Synthetic Disease Modifying Drugs in Psoriatic Arthritis

Cite this